Advertisement

Topics

Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and Chemotherapy

01:00 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Perjeta plus Herceptin and chemotherapy showed a statistically significant improvement in invasive disease-free survival (iDFS) for people with HER2-positive early breast cancer (EBC) compared to Herceptin and chemotherapy a...

Other Sources for this Article

Genentech
Media Contact:
Courtney Aberbach, 650-467-6800
or
Advocacy Contact:
Angela Wilson, 919-244-7758
or
Investor Contacts:
Neera Dahiya Ravindran, M.D., 650-491-5281
Karl Mahler, Ph.D., 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and Chemotherapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...